NewBridge Pharmaceuticals, a Dubai-based specialty pharma and biologics company, has raised $12m in its series B round from a local state fund and US life sciences-focused merchant bank Burrill.
Burrill, which has 24 healthcare companies as limited partners in its venture capital funds, had previously invested a reported $4m at NewBridge’s launch in 2007.
Kuwait Life Sciences Company, part of the National Technology Enterprises Company, that acts as a strategic investor to bring global technologies to the country’s government and businesses, is the other investor in NewBridge’s B round.
NewBridge provides healthcare products to the AfMET – Africa, Middle East, Turkey and Caspian – region.